Dipexium Pharmaceuticals $DPRX nosedived about 85% amid heavy volume trading in response to its announcement that both pivotal Phase 3 clinical studies, OneStep-1 and OneStep-2, evaluating lead product candidate Locilex (pexiganan cream 0.8%) for the treatment of mild infections of foot ulcers failed to show superiority over vehicle (placebo) plus standard wound care.